AgingResearch.NewsJoin free

Advanced Research Projects Agency for Health

OrganisationROR

Trials

Sources: clinicaltrials.gov

Awards made

  • Draper

    US$7.3m, 7 Oct 2026

  • University of Rochester

    PROSPR, PROSPR: a compound with an established human safety profile and high potency within its class, tested for aging-related outcomes, 24 Feb 2026

  • Linnaeus Therapeutics

    PROSPR, PROSPR: a once-daily compound with an established safety profile and cardiometabolic benefits, tested for aging outcomes, 24 Feb 2026

  • Cambrian Bio

    PROSPR, PROSPR: a daily oral rapamycin analogue, tested for aging outcomes, 24 Feb 2026

  • Apollo Alpha

    PROSPR, PROSPR: an oral, brain-penetrant compound targeting energy homeostasis, lipid metabolism and inflammation, tested for aging outcomes, 24 Feb 2026

  • Columbia University

    PROSPR, PROSPR: biomarkers that respond to interventions improving aging outcomes, from a combined analysis of earlier intervention trials (Mailman School of Public Health), 24 Feb 2026

  • The University of Texas Health Science Center at San Antonio

    PROSPR, PROSPR: VITAL-H (Validation and Intervention Testing for Aging, Longevity and Healthspan), a phase 3 trial of rapamycin, dapagliflozin and semaglutide against placebo in 726 adults in their 60s, led by the Barshop Institute, US$38m, 2026, 24 Feb 2026

  • Stanford University

    PROSPR, PROSPR: a healthspan score (PROSPR-IC) from existing health datasets, tested in a one-year lifestyle intervention with in-home digital assessment, 24 Feb 2026

Sources: prnewswire.com, arpa-h.gov, news.uthscsa.edu

Funded papers

Sources: api.crossref.org

Named in competing interests

Sources: pubmed.ncbi.nlm.nih.gov

Papers